Tumor lysis syndrome signal with the combination of encorafenib and binimetinib for malignant melanoma: a pharmacovigilance study using data from the FAERS database
ObjectiveTo investigate the potential association between tumor lysis syndrome (TLS) and drugs for the treatment of malignant melanoma (MM).MethodsReports of TLS recorded in the FDA Adverse Event Reporting System (FAERS) (January 2004–2023q3) were identified. Demographic and clinical characteristics...
Zapisane w:
| Główni autorzy: | , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Frontiers Media S.A.
2024-09-01
|
| Seria: | Frontiers in Pharmacology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1413154/full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|